Small Pharmacy DSCSA Exemption Ends November 27, 2026 — What Changes
Last updated: August 31, 2026
If your pharmacy has been operating under the FDA's small dispenser exemption from the Drug Supply Chain Security Act (DSCSA), the clock on that exemption runs out on November 27, 2026. After that date, the enhanced drug distribution security requirements that larger dispensers have already had to meet apply to small pharmacies too. This is a plain-language summary of what's changing and who it affects — not legal advice (see the disclaimer at the bottom).
What is the small dispenser exemption?
DSCSA's enhanced drug distribution security (EDDS) requirements — electronic, package-level tracing of prescription drugs, and interoperable data exchange between trading partners — took effect for most of the pharmaceutical supply chain on November 27, 2023. The FDA recognized that smaller pharmacies needed more time to get systems and processes in place, and issued a letter granting them a temporary exemption from certain section 582 requirements, extending through November 27, 2026.
Who qualifies as a "small dispenser"
Under the FDA's guidance, a small dispenser is a corporate entity that owns a pharmacy and employs 25 or fewer full-time licensed pharmacists or pharmacy technicians in total, across all of its locations. That count is measured as of November 27, 2024 — a pharmacy that qualified then stays covered by the exemption for the full period even if it grows afterward. The FDA's letter doesn't fully address edge cases like pharmacies opening after that date or changes in ownership, so if your situation isn't clear-cut, it's worth confirming with counsel or your pharmacy association rather than assuming either way.
What changes on November 27, 2026
Once the exemption ends, small dispensers move from exemption into the same ongoing obligations everyone else already has:
- Receiving and maintaining electronic, package-level transaction data (identifier, history, statement) from trading partners for every product received
- Verifying product identifiers and being able to trace individual packages, not just lot-level records
- Having an exception-handling process in place for suspect or illegitimate product
- Notifying trading partners and the FDA within 24 hours of determining a product is illegitimate
For a pharmacy that has been relying on the exemption, this is less a single deadline and more the point where preparation has to already be finished — the systems and processes need to be working in production, not still being set up.
What to do before the deadline
- Confirm whether your pharmacy actually qualified for the exemption as of November 27, 2024, and don't assume — get it in writing from whoever tracks headcount
- Ask your wholesaler/distributor what systems they use for electronic transaction data, and whether your pharmacy can receive and verify it today
- Put a written exception-handling process in place for suspect product, if one doesn't already exist
- Keep documentation of custody and transaction records — if a question ever comes up about a specific shipment, being able to produce it quickly matters
Where this fits with the transport side
Pharma Transport doesn't replace what your wholesaler's serialization system does — but the custody-event logging and generated compliance packets it produces for each shipment are built to give you an audit-ready record of what happened in transit, which is exactly the kind of documentation that matters once EDDS obligations are no longer optional. If that's useful to see, you can sign up and try it.
This page is general information based on FDA guidance available as of the date above, not legal advice. DSCSA guidance and enforcement dates have shifted before and could again — confirm current requirements against the FDA's own DSCSA exemptions page or with counsel before relying on this for compliance decisions.